{"slug":"melanotan-ii","verification":{"valid":true,"entries":3,"head":"89ae4b9beda9ccc23e5435da6a7276b11300058953a2b258f20b608860f81557"},"count":3,"models":["grok-4.3"],"yield":{"passes":3,"energy_spent_rows":0,"total_cost_usd":0,"waste_cost_usd":0,"total_tokens":0,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok-4.3","passes":3,"cost_usd":0,"tokens_total":0,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T17:07:01.273Z","model":"grok-4.3","role":"writer","action":"draft","payload":{"title":"melanotan ii","register":"standard","body":"## Overview\nEvidence is being populated by Grok web search.","claims":[],"sources":[]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"21bf311941691077ca6bb7d479cc3854363bc776d83d7f9e5a54611aa526fef4"},{"seq":1,"id":"k2","ts":"2026-06-29T17:07:19.610Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40210573/","title":"Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?","quote":"The case of a 22-year-old female who developed a mass in the anterior maxilla after using Melanotan II, a nasal spray containing a synthetic analogue of melanocyte-stimulating hormone, is reported. ... Histological analysis confirmed the diagnosis of a mucosal malignant melanoma.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"clinical_trial","url":"https://www.trialx.com/clinical-trials/listings/337033/melanotan-ii-mt-ii-as/","title":"Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo","quote":"This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo. ... Recruiting","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"medical","url":"https://www.sciencedirect.com/science/article/pii/S2352512626002766","title":"Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use","quote":"Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use. ... Melanotan I primarily targets MC1R, whereas melanotan II is a nonselective agonist with broader systemic effects","link_status":"http_400","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"21bf311941691077ca6bb7d479cc3854363bc776d83d7f9e5a54611aa526fef4","hash":"0a81d7a1ed39c58d8fd3c9415b25e3089e6a18cf5478175d0db6e07badb2a74c"},{"seq":2,"id":"k3","ts":"2026-06-29T17:07:36.124Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41752902/","title":"Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report","quote":"This case report presents a three-month follow-up of a patient who self-administered Melanotan II injections over a period of 64 days with the goal of achieving a deeper tanning effect.","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"0a81d7a1ed39c58d8fd3c9415b25e3089e6a18cf5478175d0db6e07badb2a74c","hash":"89ae4b9beda9ccc23e5435da6a7276b11300058953a2b258f20b608860f81557"}]}